Warfarin

"Warfarin" is a descriptor in the National Library of Medicine's controlled vocabulary thesaurus, MeSH (Medical Subject Headings). Descriptors are arranged in a hierarchical structure, which enables searching at various levels of specificity.

MeSH information

Definition | Details | More General Concepts | Related Concepts | More Specific Concepts

An anticoagulant that acts by inhibiting the synthesis of vitamin K-dependent coagulation factors. Warfarin is indicated for the prophylaxis and/or treatment of venous thrombosis and its extension, pulmonary embolism, and atrial fibrillation with embolization. It is also used as an adjunct in the prophylaxis of systemic embolism after myocardial infarction. Warfarin is also used as a rodenticide.

Descriptor ID	D014859
MeSH Number(s)	D03.383.663.283.446.520.914 D03.633.100.150.446.520.914
Concept/Terms	Warfarin Warfarin 4-Hydroxy-3-(3-oxo-1-phenylbutyl)-2H-1-benzopyran-2-one Apo-Warfarin Apo-Warfarin Aldocumar Aldocumar Gen-Warfarin Gen-Warfarin Warfant Warfant Coumadin Coumadin Marevan Warfarin Potassium Warfarin Potassium Potassium, Warfarin Warfarin Sodium Warfarin Sodium Sodium, Warfarin Coumadine Coumadine Tedicumar Tedicumar

Below are MeSH descriptors whose meaning is more general than "Warfarin".

Chemicals and Drugs [D]
Heterocyclic Compounds [D03]
Heterocyclic Compounds, 1-Ring [D03.383]
Pyrans [D03.383.663]
Benzopyrans [D03.383.663.283]
Coumarins [D03.383.663.283.446]
4-Hydroxycoumarins [D03.383.663.283.446.520]
Warfarin [D03.383.663.283.446.520.914]
Heterocyclic Compounds, Fused-Ring [D03.633]
Heterocyclic Compounds, 2-Ring [D03.633.100]
Benzopyrans [D03.633.100.150]
Coumarins [D03.633.100.150.446]
4-Hydroxycoumarins [D03.633.100.150.446.520]
Warfarin [D03.633.100.150.446.520.914]

Below are MeSH descriptors whose meaning is related to "Warfarin".

Below are MeSH descriptors whose meaning is more specific than "Warfarin".

publications

Timeline | Most Recent

This graph shows the total number of publications written about "Warfarin" by people in this website by year, and whether "Warfarin" was a major or minor topic of these publications.

Bar chart showing 72 publications over 24 distinct years, with a maximum of 7 publications in 2006

To see the data from this visualization as text, click here.

Year	Major Topic	Minor Topic	Total
1993	2	0	2
1994	0	1	1
1995	1	0	1
1996	2	0	2
1997	2	0	2
2000	0	2	2
2002	1	1	2
2004	2	1	3
2005	2	3	5
2006	5	2	7
2007	3	3	6
2008	1	4	5
2009	1	5	6
2010	1	2	3
2011	0	2	2
2012	3	1	4
2013	0	1	1
2014	1	2	3
2015	1	2	3
2016	3	1	4
2017	1	1	2
2018	2	1	3
2019	0	1	1
2020	1	1	2

Below are the most recent publications written about "Warfarin" by people in Profiles.

Rhoney DH, La M, Merz M, Cook A, Owusu KA, Roels C, Blunck J, Shewmaker J, Sangha KS, Farrokh S, Lewin J, Chester KW, Human T, Bledsoe K, Greene K, Levesque M, Rocker JC, Davis G, Neyens R, Lassiter TF, Adriance SM. Inactivated Four-Factor Prothrombin Complex Concentrate Dosing Practices for Reversal of Warfarin-Related Intracranial Hemorrhage. Neurocrit Care. 2021 08; 35(1):130-138.

View in: PubMed
Lam PH, Packer M, Gill GS, Wu WC, Levy WC, Zile MR, Brar V, Arundel C, Cheng Y, Singh SN, Allman RM, Fonarow GC, Ahmed A. Digoxin Initiation and Outcomes in Patients with Heart Failure with Preserved Ejection Fraction. Am J Med. 2020 10; 133(10):1187-1194.

View in: PubMed
Sasso R, Rockey DC. Controversies in anticoagulation therapy in patients with cirrhosis. Curr Opin Gastroenterol. 2019 05; 35(3):161-167.

View in: PubMed
Coleman CI, Weeda ER, Nguyen E, Bunz TJ, Sood NA. Effectiveness and safety of rivaroxaban vs. warfarin in patients 80+ years of age with non-valvular atrial fibrillation. Eur Heart J Qual Care Clin Outcomes. 2018 10 01; 4(4):328-329.

View in: PubMed
Roberts MZ, Gaskill GE, Kanter-Washko J, Kyle TR, Jones BC, Bohm NM. Effectiveness and safety of oral anticoagulants in patients with sickle cell disease and venous thromboembolism: a retrospective cohort study. J Thromb Thrombolysis. 2018 May; 45(4):512-515.

View in: PubMed
Coleman CI, Vaitsiakhovich T, Nguyen E, Weeda ER, Sood NA, Bunz TJ, Schaefer B, Meinecke AK, Eriksson D. Agreement between coding schemas used to identify bleeding-related hospitalizations in claims analyses of nonvalvular atrial fibrillation patients. Clin Cardiol. 2018 Jan; 41(1):119-125.

View in: PubMed
Brodie MM, Newman JC, Smith T, Rockey DC. Severity of Gastrointestinal Bleeding in Patients Treated with Direct-Acting Oral Anticoagulants. Am J Med. 2018 05; 131(5):573.e9-573.e15.

View in: PubMed
Pan KL, Singer DE, Ovbiagele B, Wu YL, Ahmed MA, Lee M. Effects of Non-Vitamin K Antagonist Oral Anticoagulants Versus Warfarin in Patients With Atrial Fibrillation and Valvular Heart Disease: A Systematic Review and Meta-Analysis. J Am Heart Assoc. 2017 Jul 18; 6(7).

View in: PubMed
Weeda ER, Peacock WF, Fermann GJ, Baugh CW, Wells PS, Ashton V, Crivera C, Wildgoose P, Schein JR, Coleman CI. Shortened hospital length of stay and lower costs associated with rivaroxaban in patients with pulmonary embolism managed as observation status. Int J Clin Pract. 2017 Jan; 71(1).

View in: PubMed
Weeda ER, Wells PS, Peacock WF, Fermann GJ, Baugh CW, Ashton V, Crivera C, Wildgoose P, Schein JR, Coleman CI. Hospital length-of-stay and costs among pulmonary embolism patients treated with rivaroxaban versus parenteral bridging to warfarin. Intern Emerg Med. 2017 Apr; 12(3):311-318.

View in: PubMed

People

Explore

Similar Concepts

Top Journals